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Background: Osteoprotegerin (OPG), a soluble member of the tumor necrosis factor receptor superfamily that
inhibits bone resorption, has been suggested as a potential marker of cardiovascular risk. This study aimed to assess
the relationship between insulin resistance, lipid profile and OPG levels in obese and non-obese sub-Saharan
African women.
Methods: Sixty obese (44) and non-obese (16) volunteer women aged 18 to 40 years were recruited in this
cross-sectional study. Their clinical (age, height, weight, waist circumference, systolic and diastolic blood pressures)
and biochemical parameters (fasting blood glucose, total cholesterol, high density lipoprotein-cholesterol (HDL-C))
were measured using standard methods. Insulin levels were measured using an electrochemiluminescence
immunoassay, while OPG levels were measured using the ELISA technique. Low density lipoprotein-cholesterol
(LDL-C), body mass index (BMI) and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) were calculated
using standard methods. Abdominal obesity was defined as a waist circumference ≥ 80 cm.
Results: OPG levels were higher in obese than in normal subjects, though the difference was not significant (p = 0.9).
BMI, waist circumference, percent body fat and systolic blood pressure were significantly higher in obese than in
non-obese subjects (p < 0.05). In these subjects, only age significantly correlated with OPG levels (r = 0.831, p = 0.003),
while none of the anthropometric nor metabolic parameter did, even after adjustment for age. In obese subjects,
OPG levels fairly correlated with HDL-C (r = 0.298, p = 0.058), and significantly correlated with HOMA-IR (r = −0.438,
p = 0.018). After adjustment for age, OPG levels remained negatively correlated to HOMA-IR (r = −0.516, p = 0.020)
and LDL-C (r = −0.535, p = 0.015) and positively correlated to HDL-C (r = 0.615, p = 0.004). In multiple linear regression
analysis, age was a main determinant of OPG levels in non-obese (β = 0.647, p = 0.006) and obese (β = 0.356, p = 0.044)
women. HDL-C was also associated to OPG levels in obese women (β = 0.535, p = 0.009).
Conclusion: The positive correlation of OPG with HDL-C and HOMA-IR, and its negative correlation with LDL-C suggest
that it may be a marker of insulin sensitivity/resistance and atherogenic risk in obese African women.
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Table 1 General characteristics of the study population
Characteristics Non obese Obese p
Age (years) 27.44 (6.07) 31.86 (5.23) 0.012
BMI (kg/m2) 22.09 (1.89) 30.35 (5.86) 0.000
Waist circumference (cm) 73.44 (4.29) 96.91 (12.94) 0.000
% body fat 19.76 (5.52) 32.03 (8.68) 0.000
Systolic arterial pression (mmHg) 110 (18) 122 (18) 0.012
Diastolic arterial pression (mmHg) 74 (11) 82 (16) 0.103
Blood glucose (mmol/L) 4.63 (0.63) 5.04 (2.01) 0.933
Triglycerides (mmol/L) 1.21 (0.47) 1.26 (0.50) 0.894
LDL-Cholesterol (mmol/L) 1.84 (0.90) 1.69 (1.06) 0.387
HDL-Cholesterol (mmol/L) 2.23 (0.59) 2.06 (0.83) 0.385
Insulin (UI/ML) 2.25 (0.55) 3.85 (0.65) 0.207
HOMA-IR 9.19 (7.60) 14.50 (12.58) 0.126
Osteoprotegerin (pmol/L) 4.14 (1.84) 4.16 (1.78) 0.900
Data are mean (standard deviation)
BMI: body mass index; % Body fat: percentage of body fat; LDL-Cholesterol:
Low density lipoprotein cholesterol; HDL-Cholesterol: High density lipoprotein
cholesterol; HOMA-IR: Homeostasis Model assessment of insulin resistance
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Osteoprotegerin (OPG) is a soluble glycoprotein that be-
longs to the tumor necrosis factor receptor super-family
[1]. It acts as a decoy soluble receptor for the receptor
activator of nuclear factor kB ligand (RANKL) [2], thus
preventing RANKL from binding its receptor on osteo-
clasts, thereby inhibiting osteoclastogenesis [3]. Some
studies showed that OPG may modulate vascular calcifi-
cation, endothelial dysfunction and left ventricular dys-
function [4–7]. OPG was also found associated to ischemic
heart disease, stroke and all-cause mortality in patients
with heart failure [4, 8–10]. Furthermore, a relation be-
tween OPG and insulin sensitivity was seen in an ageing
male population, and in obese and non-obese individuals
[11, 12]. There is therefore a need to further investigate the
potential of OPG as a marker of cardiovascular risk in di-
verse ethnic populations. This study aimed to assess the re-
lationship between insulin resistance, lipid profile and
OPG levels in obese and non-obese sub-Saharan African
women.
Methods
This was a cross-sectional study. Sixty women aged 18 to
40 years, of which 44 obese and 16 non obese were re-
cruited within the general population of Edéa, Cameroon.
For each participant we measured height, waist circumfer-
ence to the nearest 0.5 cm, and weight in light clothes to
the nearest 0.1 kg, and we then calculated the body mass
index (BMI) as weight in kg/height2 in m2. We measured
resting blood pressures using standardized procedures
with an automatic sphygmomanometer Omron HEM-705
CP (Omron Corporation, Tokyo, Japan). Fasting blood
glucose was obtained with the Accu-Chek® Compact
Plus glucometer (F. Hoffmann-La Roche AG, Basel,
Switzerland). Serum cholesterol (cholesterol oxidase
phenol4-amino antipyrene peroxidase method), serum
triglycerides (glycerol phosphatase oxidase-phenol4-amino
antipyrene peroxidase method), and high-density lipo-
protein (HDL)-cholesterol (cholesterol oxidase phenol4-
amino antipyrene peroxidase method) were measured on
a spectrophotometer (UV Mini 1240) using Chronolab
kits (Chronolab Systems, Barcelona, Spain). Low-density
lipoprotein (LDL)-cholesterol was calculated using the
Friedwald’s formula [13]. Insulin levels were measured
using an electrochemiluminescence immunoassay (Roche
Diagnostics, Indianapolis, USA), while OPG levels were
measured using Osteoprotegerin ELISA kit (Immunodiag-
nostic systems, Fontain Hill, USA). Homeostasis Model
Assessment of Insulin Resistance (HOMA-IR) calculated as
HOMA ‐ IR = (Fasting insulin × Fasting blood glucose) ÷
22.5. Abdominal obesity was defined as a waist circum-
ference ≥ 80 cm.
Data were coded, entered and analyzed using the Stat-
istical Package for Social Science (SPSS) version 20.0 forWindows (IBM Corp. Released 2011. IBM SPSS Statistics
for Windows, Version 20.0. Armonk, NY: IBM Corp.).
Variables were expressed as mean with standard deviation
(SD). The Student t-test was used to compare the obese
and non-obese groups with respect to clinical and bio-
logical parameters. Pearson’s correlation and partial correl-
ation were used to determine unadjusted and adjusted
correlates of OPG levels in obese women. Multiple step-
wise linear regression analyses were performed to deter-
mine the metabolic correlates of OPG levels in obese and
non-obese women. A p value < 0.05 was considered statis-
tically significant.
The study was approved by the National Ethical Re-
view Board of the Cameroon Ministry of Public Health.
Written informed consent was obtained from all the par-
ticipants. The study was conducted in accordance with
the Helsinki Declaration.
Results
Sixty women (44 obese and 16 non-obese) were recruited.
Obese women were significantly older than non-obese
(mean age: 31.86 ± 5.23 vs 27.44 ± 6.07; p = 0.012). BMI,
waist circumference, systolic blood pressure and percent
body fat levels were significantly higher in obese than in
non-obese subjects (p<0.05). OPG levels were comparable
among both groups (Table 1).
In non-obese subjects, only age significantly correlated
with OPG levels (r = 0.831, p = 0.003), while none of the
anthropometric nor metabolic parameters did, even after
adjustment for age. As shown in Table 2, in obese subjects,
OPG levels were almost correlated with HDL-C (r =
0.298, p = 0.058), and were significantly correlated with
HOMA-IR (r = −0.438, p = 0.018). After adjustment for
Table 2 Unadjusted and adjusted metabolic correlates of
osteoprotegerin in obese women
Correlates Model 1 Model 2
Correlation coefficient (r)
LDL-Cholesterol −0.057 −0.535*
HDL-Cholesterol 0.298 0.615**
HOMA-IR −0.438* −0.516*
Model 1: Unadjusted correlates
Model 2: Adjusted correlates (adjustment for age)
LDL-Cholesterol: Low density lipoprotein cholesterol; HDL-Cholesterol: High
density lipoprotein cholesterol; HOMA-IR: Homeostasis model assessment of
insulin resistance
*p<0.05; **p<0.01
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HOMA-IR (r = −0.516, p = 0.020) and LDL-C (r = −0.535,
p = 0.015) and positively correlated to HDL-C (r = 0.615,
p = 0.004).
In multiple stepwise regression analysis (Table 3), age
was a main determinant of OPG levels in non-obese
(β =0.647, p = 0.006) and obese (β =0.356, p = 0.044)
women. HDL-C was also associated to OPG levels in
obese women (β = 0.535, p = 0.009).
Discussion
The aim of this study was to assess the relationship be-
tween insulin resistance, lipid profile and OPG levels in
obese and non-obese sub-Saharan African women. Age
significantly correlated with OPG levels in both groups.
After adjustment for age, only HDL-C levels, LDL-C
levels, and HOMA-IR correlated with OPG levels in
obese, but not non-obese women.
OPG levels have been associated with a high risk of
cardiovascular disease in humans [14, 15]. This result
has long been a matter of controversy in the literature,
possibly because of different sizes of the study popula-
tions and of different methodologies [4]. Even in our
previous study carried out on an older population made
up of both sexes, HDL-C levels did not correlate with
OPG levels [16]. Some observational studies showed an
association between elevated serum OPG levels and clin-
ical cardiovascular disease [11, 12, 17, 18]. Unlike these
studies, we found that HDL-C which has a protective ef-
fect on heart and vessels in humans [19], was positively
correlated with OPG levels. Additionally, LDL-C whichTable 3 Linear regression associating osteoprotegerin levels
with age and metabolic parameters
Correlates Non obese Obese
Coefficient (β)
Age 0.647** 0.356*
HDL-Cholesterol 0.064 0.535**
Triglycerides −0.429* −0.019
HDL-Cholesterol: High density lipoprotein cholesterol
*p<0.05; **p<0.01carries a proatherogenic profile was negatively correlated
to OPG. These findings are consistent with evidence
from many animals studies that found a protective role
for OPG on the vasculature [20].
We found that HOMA-IR was negatively correlated
with OPG levels in obese women, indicating that ele-
vated OPG levels may be suggestive of high insulin sen-
sitivity. Contrariwise, in a study among Caucasian obese,
HOMA-IR was positively correlated to OPG levels [10].
Although our findings along with those of previous stud-
ies suggest that serum OPG may be a marker of insulin
sensitivity/resistance in obese individuals [10, 12], whether
elevated serum OPG levels reflect insulin sensitivity or
resistance in this particular population remains contro-
versial. Differences in ethnic background, metabolic
conditions and diagnostic criteria of insulin sensitivity
using HOMA-IR in the populations studied may partly ex-
plain this inconsistency. Indeed, it has been shown that
cut-off values of HOMA-IR are defined by population-
based percentiles criteria. Furthermore, these cut-off
values are different according to ethnicity, clinical
methods of estimation, and metabolic conditions of
populations studied [21]. To the best of our know-
ledge, there is no reference values for HOMA-IR that
have been validated in our population. However, we
conducted a study that showed that the performance
of fasting insulin sensitivity indices in predicting insu-
lin sensitivity among Black Africans are not optimal
[22]. Overall, discrepancy between our results and
some previous reports in Caucasians regarding the re-
lationship between OPG levels and lipid profile and
HOMA-IR [10, 12] stresses the need for further inves-
tigation with an emphasis on ethnic differences.
The main limitation of this study is its small sample
size which hampered definitive inferences and drawing
relevant conclusions. Thus, our findings need to be veri-
fied in further large population studies.
Conclusion
The positive correlation of OPG with HDL-C and HOMA-
IR, and its negative correlation with LDL-C suggest that
it maybe a marker of insulin sensitivity/resistance and
atherogenic risk in obese African women. Further large
studies are needed to verify these findings.
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